Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer

Author： Cremolini Chiara Schirripa Marta Loupakis Fotios Falcone Alfredo

ISSN： 1758-194X

Source： Colorectal Cancer, Vol.2, Iss.5, 2013-10, pp. : 411-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

How I Treat Metastatic Colorectal Cancer: Incorporating Regorafenib into Therapy

By Scheithauer Werner Ychou Marc

The Journal of OncoPathology, Vol. 2, Iss. 2, 2014-06 ,pp. : 11-18

Optimal Clinical Ltd

Access to resources Recommend Favorite

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report

By Kawasaki Kenta Hamamoto Yasuo Adachi Masayuki Kanai Takanori Takaishi Hiromasa

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 231-233

Spandidos Publications

Access to resources Recommend Favorite

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

The Oncologist, Vol. 23, Iss. 1, 2018-01 ,pp. : 7-15

John Wiley & Sons Inc

Access to resources Recommend Favorite

XELIRI compared with FOLFIRI as a secondline treatment in patients with metastatic colorectal cancer

Oncology Letters, Vol. 8, Iss. 4, 2014-01 ,pp. : 1864-1872

Spandidos Publications

Access to resources Recommend Favorite

A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients

By Ogawa Kohei Ueno Takao Kato Ken Nishitani Hitoshi Akiyoshi Kohei Iwasa Satoru Nakajima Takako Hamaguchi Tetsuya Yamada Yasuhide Hosokawa Ayumu Sugiyama Toshiro Shimada Yasuhiro

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1020-1024

Springer Publishing Company

Access to resources Recommend Favorite